These trials include nivolumab (an immune checkpoint inhibitor) for melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC) (clinicaltrials.gov ID: NCT02771626); everolimus (an mTOR inhibitor) for RCC (clinicaltrials.gov ID: NCT03163667); palbociclib (a CDK4/6 inhibitor) for KRAS-mutated pancreatic ductal adenocarcinoma (PDAC), NSCLC, and colorectal cancer (CRC) (clinicaltrials.gov ID: NCT03965845); and cabozantinib (a tyrosine kinase inhibitor) for advanced RCC (clinicaltrials.gov ID: NCT03428217). Here, KRAS is linked to non-small cell lung carcinoma.